Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Cathie Wood | ARK Investment Management LLC | 0.0% | -0.00% |
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | -0.00% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | -0.00% |
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of MDWD is 29.8 and suggests 124% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre